Verona Pharma plc
VRNA
$58.92
$0.621.06%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 551.44% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 551.76% | -- | |||
| Cost of Revenue | 275.51% | -- | |||
| Gross Profit | 581.28% | -- | |||
| SG&A Expenses | 28.10% | -28.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.84% | -33.88% | |||
| Operating Income | 54.47% | 42.21% | |||
| Income Before Tax | 40.17% | 38.83% | |||
| Income Tax Expenses | 3,208.40% | -75.35% | |||
| Earnings from Continuing Operations | 21.26% | 39.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 21.26% | 39.35% | |||
| EBIT | 54.47% | 42.21% | |||
| EBITDA | 54.82% | 42.37% | |||
| EPS Basic | 22.61% | 39.69% | |||
| Normalized Basic EPS | 41.18% | 35.82% | |||
| EPS Diluted | 16.43% | 39.69% | |||
| Normalized Diluted EPS | 41.18% | 35.82% | |||
| Average Basic Shares Outstanding | 1.74% | 0.57% | |||
| Average Diluted Shares Outstanding | 1.74% | 0.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||